(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 13.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Genmab A's revenue in 2025 is $3,317,340,000.On average, 21 Wall Street analysts forecast GMAB's revenue for 2025 to be $238,204,745,102, with the lowest GMAB revenue forecast at $223,000,186,904, and the highest GMAB revenue forecast at $251,035,595,902. On average, 21 Wall Street analysts forecast GMAB's revenue for 2026 to be $277,018,068,772, with the lowest GMAB revenue forecast at $250,907,287,394, and the highest GMAB revenue forecast at $310,057,509,582.
In 2027, GMAB is forecast to generate $314,612,461,616 in revenue, with the lowest revenue forecast at $275,799,137,946 and the highest revenue forecast at $348,485,907,728.